SIME Announces Exclusive Agreement for Commercialisation of Respiratory Diagnostic Platform

Partnership will accelerate path to commercialisation of novel respiratory diagnostics

SIME, a Clinical AI company specialising in rapid ICU diagnostics, announced it has entered into an exclusive agreement with an existing strategic investor to commercialise the company’s point-of-care products and services in Latin America.

The first product to market, a breakthrough diagnostic test clinically proven to predict neonatal respiratory disease, will be marketed to pioneering Neonatal Intensive Care Units (NICUs) across the continent. Powered by a patented AI platform, this novel technology enables preventative and precision medicine in premature babies moments after birth.

Recommended AI News: Micro Focus Introduces File Analysis Suite to Reduce Risk Associated With GDPR

“The need for rapid respiratory diagnostics in intensive care has never been greater,” said SIME CEO Povl Verder. “And as the only company in the world able to rapidly predict pre-symptomatic lung disease in an acute setting, we are uniquely positioned to address this urgent unmet need. Our AI Platform enables doctors to deliver early and decisive respiratory treatment, reducing or diminishing the need for invasive ventilation and therapeutics.”

Recommended AI News: Intuitive Technology Partners Achieves Its 4th VMware Master Services Competency in Cloud Management & Automation

The agreement includes milestone payments as well as access to the commercial partner’s extensive market capabilities. This collaboration will significantly accelerate SIME’s path to commercialisation in Latin America, generate substantial revenue and advance partnerships in China, Europe and the US.

Recommended AI News: Flexential Announces Its Largest Data Center Expansion to Date, Meeting IT Infrastructure Needs During the Pandemic and Beyond